9.38 USD
▲+0.36+3.99%
盘后 9.02 0.00%
2026-08-03
市值
$1.28B
市盈率
—
EPS
-1.97
股息率
—
52 周区间
5.05 – 12.41
成交量
442.26K
Beta
1.32
目标价
18.89
52W 低 5.0552W 高 12.41
价格走势
公司简介
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy produ...